MDACC Study No:2010-0041 ( NCT No: NCT00940602)
Title:A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1risk) and transfusional iron overload (TELESTO)
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Deferasirox
Study Status:Closed
Study Description:The goal of this clinical research study is to study the effectiveness of the
drug ExjadeŽ (deferasirox) in controlling MDS. Researchers will also study the
effect of the study drug/placebo on the heart, kidneys, and liver.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Deferasirox
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis Pharmaceuticals
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults